September 6, 2011
Roche of Switzerland has announced that the European Commission approved on September 1 the anticancer agent Tarceva (erlotinib) for use in patients with a genetically distinct type of non-small cell lung cancer (NSCLC) as an additional indication. Tarceva is already...read more